Provided is a novel technique for controlling the blood-brain barrier. An antibody whose epitope is a region within an extracellular domain of Claudin 5 protein.

Disclosed is a means of enabling the construction of a more accurate PIVKA-II immunoassay system using monoclonal antibodies against human prothrombin. The PIVKA-II assay method according to the present invention comprises measuring PIVKA-II in a sample by an immunoassay using an anti-PIVKA-II antibody or an antigen-binding fragment thereof which specifically binds to PIVKA-II and a mixture of a first anti-prothrombin antibody or an antigen-binding fragment thereof which recognizes hydrophilic PIVKA-II molecules and a second anti-prothrombin antibody or an antigen-binding fragment thereof which recognizes hydrophobic PIVKA-II molecules.

Disclosed is a means of enabling the construction of a more accurate PIVKA-II immunoassay system using monoclonal antibodies against human prothrombin. The PIVKA-II assay method according to the present invention comprises measuring PIVKA-II in a sample by an immunoassay using an anti-PIVKA-II antibody or an antigen-binding fragment thereof which specifically binds to PIVKA-II and a mixture of a first anti-prothrombin antibody or an antigen-binding fragment thereof which recognizes hydrophilic PIVKA-II molecules and a second anti-prothrombin antibody or an antigen-binding fragment thereof which recognizes hydrophobic PIVKA-II molecules.

This invention provides an anti-REIC antibody that specifically recognizes a cancer-associated protein (REIC/Dkk-3) and enables monitoring of cancer treatment effects involving the use of the REIC/Dkk-3 gene or the REIC/Dkk-3 protein as a medicine. This invention also provides a method of diagnosis involving the use of such antibody. The method of diagnosis comprises a method of cancer detection comprising: measuring the REIC/Dkk-3 protein concentration in the biological sample obtained from a subject with the use of a first antibody or a functional fragment thereof that specifically recognizes the REIC/Dkk-3 protein having an active structure produced by a normal cell but does not recognize and bind to the REIC/Dkk-3 protein existing at a high level in the blood from a cancer patient or has low reactivity with the REIC/Dkk-3 protein existing at a high level in the blood from a cancer patient; and, when the REIC/Dkk-3 protein concentration in the biological sample obtained from the subject is lower than the REIC/Dkk-3 protein concentration in the biological sample from a healthy individual, determining that the subject is suffered from precancer or a neoplastic disease.

This invention provides an anti-REIC antibody that specifically recognizes a cancer-associated protein (REIC/Dkk-3) and enables monitoring of cancer treatment effects involving the use of the REIC/Dkk-3 gene or the REIC/Dkk-3 protein as a medicine. This invention also provides a method of diagnosis involving the use of such antibody. The method of diagnosis comprises a method of cancer detection comprising: measuring the REIC/Dkk-3 protein concentration in the biological sample obtained from a subject with the use of a first antibody or a functional fragment thereof that specifically recognizes the REIC/Dkk-3 protein having an active structure produced by a normal cell but does not recognize and bind to the REIC/Dkk-3 protein existing at a high level in the blood from a cancer patient or has low reactivity with the REIC/Dkk-3 protein existing at a high level in the blood from a cancer patient; and, when the REIC/Dkk-3 protein concentration in the biological sample obtained from the subject is lower than the REIC/Dkk-3 protein concentration in the biological sample from a healthy individual, determining that the subject is suffered from precancer or a neoplastic disease.

The present invention provides a method to rapidly screen tumor cells for invasive and metastatic characteristics, heterogeneity and their response to therapeutic agents, and provides a multi-well microinjection system for the automated imaging and microinjection of zebrafish embryos.

The present invention provides a method to rapidly screen tumor cells for invasive and metastatic characteristics, heterogeneity and their response to therapeutic agents, and provides a multi-well microinjection system for the automated imaging and microinjection of zebrafish embryos.

Provided are an IL-5 antibody, an antigen binding fragment thereof, and a medical application therefor. The present invention comprises a mouse-derived antibody containing an IL-5 antibody CDR region, a chimeric antibody, a humanized antibody, and a pharmaceutical composition comprising said IL-5 antibody and said antigen binding fragment thereof, as well as the use of the pharmaceutical composition as a drug.

Provided is a novel technique for controlling the blood-brain barrier. An antibody whose epitope is a region within an extracellular domain of Claudin 5 protein.

Disclosed is an antibody which binds to olanzapine, which can be used to detect olanzapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of olanzapine, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.